If you have been reading about nuclear receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
In October 2023, former Mongolian president Elbegdorj Tsakhia wrote to CNN, expressing his opposition to the death penalty and he cited Singapore as an example. Stating that Mongolia had abolished capital punishment and the crime rate in Mongolia never increased in the aftermath, Elbegdorj stated that he was concerned with the past 16 executions of low to mid-level drug traffickers in Singapore since March 2022, especially the July 2023 hanging of Saridewi Djamani (Singapore's first female to be put to death since 2004), and while he avers his respect for Singapore in terms of its prosperity and stability, Elbegdorj hoped that Singapore could re-evaluate the effectiveness of using the death penalty to curb drug crimes in favour of eventual abolition, due to the death penalty not able to fully uproot the cause of drug trafficking. He also stated that with the newly elected president Tharman Shanmugaratnam taking office, he hoped that the president could affirm the presidential powers of granting clemency to those on death row to soften the government's retentionist stance on capital punishment. In 2024, anti-death penalty activist Kokila Annamalai was the first activist within Singapore to publicly refuse to comply with the Protection from Online Falsehoods and Manipulation Act (POFMA) after the Singaporean government accused her of posting false information about its actions on social media concerning its use of the death penalty.
== Litigation == On September 7, 2018, the SEC filed a lawsuit against a number of individuals and entities including Opko Health and the CEO and chairman, Phillip Frost. In December 2018, the company and Dr. Frost entered into settlements with the SEC, which, upon approval by the court in January 2019, resolved the claims. Without admitting or denying any of the allegations, the company agreed to an injunction from violations of Section 13(d) of the “Exchange Act”, a strict liability claim, and to pay a $100,000 penalty, which has been paid. On March 8, 2019, the SEC filed an amended complaint, with OPKO paying US$100,000 "Without admitting or denying the SEC's allegations."
Oxygen primary ions are often used to investigate electropositive elements due to an increase of the generation probability of positive secondary ions, while caesium primary ions often are used when electronegative elements are being investigated. For short pulsed ion beams in static SIMS, LMIGs are most often deployed for analysis; they can be combined with either an oxygen gun or a caesium gun during elemental depth profiling, or with a C60+ or gas-cluster ion source during molecular depth profiling.
=== Analogues === Pyridopyrroloquinoxaline serotonin 5-HT2A receptor agonists such as the psychedelic IHCH-7113 and the non-hallucinogenic IHCH-7086, IHCH-7079, and ITI-1549 have been derived via structural modification of lumateperone.
The UGR comes in two menu variations: breakfast and lunch/dinner. Menus are intended to be cycled through regularly. They include both standard American cuisine and diverse cuisines. The UGR-E also has a unique holiday menu variant. UGR modules come with mandatory and optional meal supplements—namely UHT milk, cereal, bread, fruits, vegetables, salads, drink mixes, and condiments—as well as eating utensils, kitchen utensils, disposable mess trays, cups, napkins, and trash bags.
Sources: en.wikipedia.org
Reagent co-flow and droplet fusion methods are tied to droplet formation events which lack downstream flexibility. To decouple reagent addition from droplet creation, a setup where reagent stream flows through a channel perpendicular to the droplet stream is utilized. An injection droplet is then merged with the plug as it passes the channel. Reagent volume is controlled by the flow rate of the perpendicular reagent channel. An early challenge for such systems is that reagent droplet merging was not reproducible for stable emulsions. By adapting the use of an actuated electric field into this geometry, Abate et al. achieved sub-picoliter control of reagent injection. This approach, termed picoinjection, controls injection volume through reagent stream pressure and droplet velocity. Further work on this method has aimed to reduce pressure fluctuations that impede reproducible injections. Injection of the pressurized aqueous fluid occurs when the electrodes are activated creating an electric field that destabilizes the aqueous fluid/oil interface, triggering the injection. Key advantages of picoinjection include low inadvertent material transfer between droplets and maintenance of droplet compartmentalization through the injection, however, electrodes are often fabricated using metal-solder which can complicate construction of the microfluidic device through increased fabrication time as a result of a more intricate design.
=== Post-war expansion of the Rowett Research Institute === When Boyd Orr returned to Aberdeen in early 1919, his plan for a larger Institute had still not been accepted. Indeed, even his plans for the annual maintenance grant had to be approved by the Professor of Agriculture in Cambridge, Thomas Barlow Wood. Despite gaining the latter's support, his expansion plans were at first rebuffed, although he succeeded in having the annual grant increased to £4,000. In 1920 he was introduced to John Quiller Rowett, a businessman who seemed to have qualms of conscience over the large profits he had made during the war. Shortly afterwards, the government agreed to finance half the cost of Boyd Orr's plan, provided he could raise the other half elsewhere. Rowett agreed to provide £10,000 for the first year, £10,000 for the second year, and gave an additional £2,000 for the purchase of a farm, provided that, "if any work done at the Institute on animal nutrition was found to have a bearing on human nutrition, the Institute would be allowed to follow up this work", a condition the Treasury was willing to accept. By September 1922 the buildings were nearly completed, and the renamed Rowett Research Institute was opened shortly thereafter by Queen Mary. Boyd Orr proved to be an effective fund-raiser from both government and private sources, expanding the experimental farm to around 1,000 acres (400 hectares), building a well-endowed library, and expanding the buildings.
== Cast == Joe Shishido as Shintaro Ibuki Yumiko Nogawa as Borneo Maya Kōji Wada as Abe Tomiko Ishii as Roku Kayo Matsuo as Mino Misako Tominaga as Machiko Keisuke Noro as Ishii Chico Lourant as Catholic Priest Isao Tamagawa as Horidome Satoko Kasai as Komasa Sen
=== Acidity === Thiols are easily deprotonated. Relative to the alcohols, thiols are more acidic. The conjugate base of a thiol is called a thiolate. Butanethiol has a pKa of 10.5 vs 15 for butanol. Thiophenol has a pKa of 6, versus 10 for phenol. A highly acidic thiol is pentafluorothiophenol (C6F5SH) with a pKa of 2.68. Thus, thiolates can be obtained from thiols by treatment with alkali metal hydroxides.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.